On May 9, 2025, Hansoh Pharmaceutical announced that a new indication for Ameile (almonertinib mesylate tablets) has been approved for marketing. The new indication is for the adjuvant treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) mutations, and who have undergone tumor resection. Ameile now has four approved indications in China, maintaining its leading position among domestically developed third-generation EGFR-TKIs.
This approval is primarily based on the ARTS study (HS-10296-302), a randomized, double-blind, controlled, multicenter Phase III clinical trial. The study results were presented as an oral report at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
Data from the ARTS study presented at the 2025 AACR Annual Meeting confirmed that for patients with completely resected stage II–IIIB EGFR-mutant NSCLC, adjuvant treatment with Ameile—when applicable—can significantly improve disease-free survival (DFS). The 2-year DFS rate reached 90.2%, with an HR of 0.17, and the overall safety profile was manageable. Notably, the study enrolled only Chinese patients, highlighting the significant efficacy and manageable safety profile of the domestically developed EGFR-TKI in the Chinese population.
About Ameile
As China’s first original third-generation EGFR-TKI, Ameile (Aumolertinib Mesilate Tablets) features good liposolubility and stability, allowing it to better penetrate the blood-brain barrier with a low incidence of adverse reactions. Currently, Ameile has been approved for four indications: second-line treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy; first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive; treatment of patients with locally advanced, unresectable（Stage III）non-small cell lung cancer (“NSCLC”) whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have epidermal growth factor receptor (“EGFR”) exon 19 deletions or exon 21 (L858R) substitute mutations; adjuvant treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) mutations, and who have undergone tumor resection.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
Email：myimmnet@163.com
Post time: May-13-2025